Company profile for Spexis

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Spexis , Headquartered in Switzerland and Boston, two global biotech-hubs, our ambition is to develop Spexis into a leading biopharmaceutical company with a strategic focus on rare diseases, oncology and antimicrobial resistance. With a strong scientific core, our drug discovery and research efforts are led by our in house scientist via leveraging our discovery platforms in collaboration with top academic centers around the gl...
Spexis , Headquartered in Switzerland and Boston, two global biotech-hubs, our ambition is to develop Spexis into a leading biopharmaceutical company with a strategic focus on rare diseases, oncology and antimicrobial resistance. With a strong scientific core, our drug discovery and research efforts are led by our in house scientist via leveraging our discovery platforms in collaboration with top academic centers around the globe. We have two clinical programs focused on products for rare, chronic respiratory diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
Hegenheimermattweg 125 CH-4123, Allschwil
Telephone
Telephone
+41 61 567 16 00
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com//news-release/2023/11/01/2770774/0/en/Spexis-Announces-Changes-to-the-Executive-Committee.html

GLOBENEWSWIRE
01 Nov 2023

https://www.globenewswire.com//news-release/2023/10/06/2755891/0/en/Spexis-to-host-business-update-conference-call-on-October-9-2023.html

GLOBENEWSWIRE
06 Oct 2023

https://www.globenewswire.com//news-release/2023/09/29/2751738/0/en/Spexis-provides-business-update-and-announces-financial-results-for-the-first-half-of-2023.html

GLOBENEWSWIRE
29 Sep 2023

https://www.globenewswire.com//news-release/2023/09/28/2750884/0/en/Spexis-announces-the-appointment-of-Gon%C3%A7alo-Bernardes-Ph-D-as-acting-Head-of-Chemical-Biology.html

GLOBENEWSWIRE
28 Sep 2023

https://www.globenewswire.com/news-release/2023/08/15/2725169/0/en/Spexis-announces-USD-2-5-million-capital-commitment-to-support-the-upcoming-Phase-3-ColiFin-studies.html

GLOBENEWSWIRE
15 Aug 2023

https://www.globenewswire.com/news-release/2023/06/30/2697522/0/en/Spexis-announces-engagement-with-Maxim-Group-LLC-as-M-A-advisor-to-support-evaluation-of-strategic-transactions.html

GLOBENEWSWIRE
30 Jun 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty